Genome Signature (HRD) - Homologous Recombination Deficiency

What is GENOME SIGNATURE (HRD) test?

The Genome Signature HRD (Homologous Recombination Deficiency) test is a comprehensive genomic assay that evaluates the overall DNA repair capability of tumor cells.

• It assesses mutations in HRR genes (homologous recombination repair genes) along with genomic instability markers.

• Key components of the test include:

  1. HRR Genes: Detects mutations in genes responsible for DNA double-strand break repair.

  2. Genomic Instability Score : Measures the level of DNA damage and chromosomal instability in the tumor.

  3. Loss of Heterozygosity (LOH): Evaluates regions where one allele of a gene is lost, indicating genomic instability.

• This test provides a composite picture of homologous ercombination deficiency, which can influence cancer progression and therapy response.

Why consider GENOME SIGNATURE (HRD) test in Kollam?

Genome Signature HRD (Homologous Recombination Deficiency) test  is valuable to:

• Identify tumors with homologous recombination deficiency, which are often sensitive to PARP inhibitors.

• Assess genomic instability, which is associated with aggressive tumor behavior.

• Guide personalized cancer therapy and predict response to targeted treatments.

• Support risk stratification and treatment planning in patients with ovarian, breast, prostate, or pancreatic cancers.

• Provide insight into tumor biology for precision oncology approaches.

Who should get tested for GENOME SIGNATURE (HRD) test in Kollam?

Genome Signature HRD (Homologous Recombination Deficiency) test is recommended for:

• Patients with advanced or metastatic cancers being considered for PARP inhibitor therapy.

• Individuals with tumors suspected of HRD based on family history or prior genetic testing.

• Clinicians seeking to optimize targeted therapy based on tumor genomic profile.

• Patients requiring prognostic and predictive information about tumor aggressiveness.

More Information

OTHER NAMES: HRD Genome Signature Test, Homologous Recombination Deficiency Assay, Genomic Instability Panel, hrd score test, homologous recombination deficiency, hrd assay, genomic instability score, brca-like genomic scar, hrd biomarker, parp inhibitor eligibility test

• Homologous recombination (HR) is a natural DNA repair mechanism that fixes double-strand breaks in DNA accurately using a sister chromatid as a template.

• HRD occurs when this repair pathway is defective, meaning the cell cannot properly repair DNA damage.

• This deficiency leads to genomic instability, which can drive cancer development, especially in ovarian, breast, prostate, and pancreatic cancers.

• Tumors with HRD are more sensitive to certain therapies, like:

• PARP inhibitors (e.g., olaparib, niraparib) – these block alternative DNA repair, causing cancer cell death.

• Platinum-based chemotherapies (like cisplatin, carboplatin).

• Testing for HRD helps in personalized cancer treatment.